 |
Reliable & Innovative Solutions for Transgenesis| home | contact us | |
|
| |
|
|
 |
Kader Thiam, Ph.D.
Vice President Transgenic Technologies
|
Dr. Kader Thiam received a Ph.D. for his work at the department of Cellular Immunology of the Pasteur Institute, Lille. Then he was a fellow at The Pasteur Institute, Lille, Department of Peptide Chemistry. His work was focused on the regulation of the immune response by the use of recombinant viruses or synthetic agonist of cytokine and on the cytoplasm delivery of lipopeptides to modulate pharmacological targets.
Bonnet D, Thiam K, Loing E, Melnyk O, Gras-Masse H.
Synthesis by chemoselective ligation and biological evaluation of novel cell-permeable PKC-zeta pseudosubstrate lipopeptides.
J Med Chem. 2001 Feb 1;44(3):468-71.
Loing E, Andrieu M, Thiam K, Schorner D, Wiesmuller KH, Hosmalin A, Jung G, Gras-Masse H.
Extension of HLA-A*0201-restricted minimal epitope by N epsilon-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells.
J Immunol. 2000 Jan 15;164(2):900-7.
Thiam K, Loing E, Zoukhri D, Rommens C, Hodges R, Dartt D, Verwaerde C, Auriault C, Gras-Masse H, Sergheraert C.
Direct evidence of cytoplasmic delivery of PKC-alpha, -epsilon and -zeta pseudosubstrate lipopeptides: study of their implication in the induction of apoptosis.
FEBS Lett. 1999 Oct 15;459(3):285-90.
Thiam K, Loing E, Verwaerde C, Auriault C, Gras-Masse H.
IFN-gamma-derived lipopeptides: influence of lipid modification on the conformation and the ability to induce MHC class II expression on murine and human cells.
J Med Chem. 1999 Sep 9;42(18):3732-6.
Verwaerde C, Thiam K, Delanoye A, Fernandez-Gomez R, D'Halluin J, Auriault C.
Systemic delivery of an adenovirus expressing EBV-derived vIL-10 in mice infected with Schistosoma mansoni or Leishmania amazonensis: controversial effects on the development of pathological parameters.
Eur Cytokine Netw. 1999 Jun;10(2):161-70
Thiam K, Loing E, Delanoye A, Diesis E, Gras-Masse H, Auriault C, Verwaerde C.
Unrestricted agonist activity on murine and human cells of a lipopeptide derived from IFN-gamma.
Biochem Biophys Res Commun. 1998 Dec 30;253(3):639-47.
Dr Thiam joined genOway in 1999 as Scientific Consultant and Head of the Immunology Department. Today, Dr Thiam serves the company as Vice President of Transgenic Technologies, driving the R&D programs aiming at developing new alternatives to overcome transgenesis limitations. His work allowed the company to patent 4 innovative technologies in genetic engineering field, some of them using RNAi gene knock down, and 3 proprietary animal models in immunology field.
|
|
genOway is a service provider dedicated to the development of tailor-made transgenic mouse and rat models.
With 54 full-time employees and operating in 22 countries in Europe, North America and Asia, genOway is the largest company in its field in Europe, both in terms of employees and clients.
genOway’s technology platform comprises technologies classically used in transgenesis combined with conditional and exclusive inducible systems. In addition, innovative proprietary technologies enable subsequent experimental steps in your research programs to be anticipated. genOway has patented several innovative strategies based on the design of evolving animal models to anticipate subsequent experimental steps: theses approaches enables different mouse models to be generated starting from a unique mouse model. This approach is time-saving and cost effective.
 |
genOway has established a close partnership with Invitrogen to provide a complete services platform for the in vivo use of the RNAi technology: from the design and validation of the shRNA to in vivo gene knockdown. Our services are 100 % customized: you may subcontract the entire model development or only part of it to genOway. |
|
All animal-related services are subcontracted to the world’s leading animal breeder Charles River Laboratories, ensuring first class animal housing and breeding, SOPF/SPF/VAF health status certification, worldwide delivery as well as additional services (colony scale-up & accelerated backcrossing) |
|
|
|
|
|
Transgenics (rat and mouse gene modification): knockout mouse (KO mouse), knock in mice (KI mice) and transgenic mouse
genOway, service provider in transgenesis for customized genetically modified mice and rats: gene overexpression, gene knockdown, gene knockout, etc.
| Site map | Legal Notice | © genOway 2006 |
|
|
Service offer